Eritoran, an antagonist of the LPS-MD2-TLR4 complex, which blocked LPS-induced inflammatory cytokine response in vitro and in vivo, failed to produce any discernable benefit in reducing the mortality of patients with severe sepsis in a randomized, double-blind, and placebo-controlled phase 3 clinical trial [98]. Here, TLR4 is linked to Sepsis.